Prediction of immunotherapy response using live tumor fragments from routine clinical biopsies cell.com/cell-reports-medici…

I said good bye to Dr. Karan Sood at Logan Airport this afternoon as he heads back to Mumbai, India. The time he spent with us at @BrownUniversity and @BrownUnivHealth as a @WINConsortium Precision Oncology Fellow was productive and sets the stage for future work and collaboration. @Dr_R_Kurzrock @SewantiLimaye @LiaTsimberidou @VivekSubbiah @DrChoueiri @TataMemorial

Outstanding @WIN_Consortium international MTB in precision oncology this morning including challenging cases of CRC with KRAS and PIK3CA mutation, peritoneal carcinomatosis, MPNST with NF1, AXL, SUZ12, TP53 alterations among others, and recurring CRC over many years with WT KRAS, treated liver metastases, FANCA mutation now with brain metastases @Dr_R_Kurzrock @SewantiLimaye @bcarneiro7 @DrSGraff @JerryAzzoli @LiangChengMD @IAbuGheidaMD @alshamsi2000 @VivekSubbiah @DrRoyHerbst @DCarboneMD @jrgralow @billdahutmd @drKMusallam @LiaTsimberidou @RueterJens @LussierY

Dr. Keith Flaherty, Director Exp Therapeutics, MGH, AACR President delivers Keynote entitled “Extending the Boundaries of Bedside-to-Bench Translational Research to Realize Rational Combination Therapies” at the 2026 WIN Symposium at the Rhode Island Convention Center in Providence, Rhode Island, USA. Keith T. Flaherty, MD, FAACR is a Member, Scientific Advisory Board, WIN Consortium. He is the Richard Saltonstall Chair in Oncology, Massachusetts General Hospital, Professor of Medicine at Harvard Medical School, USA and President of the American Association for Cancer Research (AACR). As described in more than 350 peer reviewed primary research reports he has authored or co-authored, Dr. Flaherty and colleagues made several seminal observations that have defined the treatment of melanoma when they established the efficacy of BRAF, MEK and combined BRAF/MEK inhibition in patients with metastatic melanoma in a series of New England Journal of Medicine articles for which Dr. Flaherty was the first or senior author. He was the principal investigator of the NCI MATCH trial, the first NCI-sponsored trial assigning patients to targeted therapy independent of tumor type on the basis of DNA sequencing detection of oncogenes. Dr. Flaherty joined the NCI Board of Scientific Advisors in 2018 (chair 2021-23), the AACR Board of Directors in 2019, and was elected President of AACR in 2025. Dr. Flaherty co-founded Loxo Oncology in 2013 and Scorpion Therapeutics in 2020, serving on the board of directors through the acquisitions of both by Eli Lilly in 2019 and 2025. He co-founded X4 Pharmaceuticals, privately held Strata Oncology (2015), Apricity Oncology (2017), Gyges Oncology (2020), Khora Therapeutics (2024), and Monimoi Therapeutics (2025). Dr. Flaherty's presentation was ~24 minutes long followed by ~18 minutes of questions by global leaders in precision oncology, AI, clinical oncology, and patient advocacy. youtube.com/watch?v=R83QStfI… @WIN_Consortium @Dr_R_Kurzrock @AACR @AACRPres @AmericanCancer @ASCO @SewantiLimaye @LiaTsimberidou @LussierY @LiangChengMD @DrRoyHerbst @VivekSubbiah @CancerConnector @JiaJennyLiu @TaberneroJosep @jrgralow @curijoey @oncodaily @Oncotarget @theNCI @NCIDirector @AACI_Cancer